Fabry nephropathy: A review - How can we optimize the management of Fabry nephropathy?

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Waldek, Stephen ^a   Feriozzi, Sandro ^b  

^a Department of Nephrology and Dialysis Belcolle Hospital ^*  (United Kingdom)

^b BELCOLLE HOSPITAL   (Italy)

Author keywords

Diagnosis; Enzyme replacement therapy; Fabry disease; Management; Nephropathy

Indexed keywords

BIOLOGICAL MARKER; AGALSIDASE ALFA; ALPHA GALACTOSIDASE; ISOENZYME;

ANTIBODY PRODUCTION; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DIALYSIS; DISEASE COURSE; EARLY INTERVENTION; ENZYME REPLACEMENT; FABRY DISEASE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; PROTEINURIA; RENOGRAPHY; REVIEW; TREATMENT RESPONSE; GENETICS; KIDNEY FUNCTION TEST; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

ALPHA-GALACTOSIDASE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; ISOENZYMES; KIDNEY FUNCTION TESTS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84901370511     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-72     Document Type: Review

References (107)

1. α-Galactosidase A deficiency: Fabry disease. Desnick RJ, Ioannou YA, Eng CM, The metabolic and molecular bases of inherited disease New York, USA: McGraw Hill, Scriver CR, Beaudet AL, Sly WS, Valle D, 8 2001 3733 3774
2. Fabry disease. Germain DP, Orphanet J Rare Dis 2010 5 30 10.1186/1750-1172-5-30 21092187
3. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M, J Inherit Metab Dis 2007 30 184 192 10.1007/s10545-007-0521-2 17347915 (Pubitemid 46487999)
4. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP, Lemay R, Tylki-Szymanska A, Wilcox WR, Pediatr Res 2008 64 550 555 10.1203/PDR.0b013e318183f132 18596579
5. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP, Mol Genet Metab 2008 93 112 128 10.1016/j.ymgme.2007.09.013 18037317
6. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Tondel C, Bostad L, Hirth A, Svarstad E, Am J Kidney Dis 2008 51 767 776 10.1053/j.ajkd.2007.12.032 18436087 (Pubitemid 351626251)
7. Natural history of Fabry disease in females in the Fabry outcome survey. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M, J Med Genet 2006 43 347 352 16227523
8. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C, Nephrol Dial Transplant 2008 23 1600 1607 10.1093/ndt/gfm848 18175781 (Pubitemid 351767751)
9. Interdisciplinary approach towards female patients with Fabry disease. Weidemann F, Niemann M, Beer M, Breunig F, Wanner C, Eur J Clin Invest 2012 42 455 462 10.1111/j.1365-2362.2011.02614.x 22049975
10. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG, Nephrol Dial Transplant 2010 25 769 775 10.1093/ndt/gfp554 19846394
11. Light- and electron-microscopic histochemistry of Fabry's disease. Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, Schuchman E, Desnick RJ, Am J Pathol 1981 103 247 262 6786101 (Pubitemid 11112979)
12. Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R, Kidney Int 1978 13 223 235 10.1038/ki.1978.32 418264 (Pubitemid 8304328)
13. Renal pathology in Fabry disease. Alroy J, Sabnis S, Kopp JB, J Am Soc Nephrol 2002 13 Suppl 2 134 138 11752030
14. Fabry disease: a morphologic study of 11 cases. Fischer EG, Moore MJ, Lager DJ, Mod Pathol 2006 19 1295 1301 10.1038/modpathol.3800634 16799480 (Pubitemid 44423075)
15. Renal ultrastructural findings in Anderson-Fabry disease. Sessa A, Toson A, Nebuloni M, Pallotti F, Giordano F, Battini G, Maglio A, Meroni M, Calconi G, Bertolone G, Gatti P, J Nephrol 2002 15 109 112 12018625 (Pubitemid 34594159)
16. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Najafian B, Svarstad E, Bostad L, Gubler MC, Tondel C, Whitley C, Mauer M, Kidney Int 2011 79 663 670 10.1038/ki.2010.484 21160462
17. Renal pathological changes in Fabry disease. Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M, Nebuloni M, Pallotti F, Giordano F, Bertagnolio B, Tosoni A, J Inherit Metab Dis 2001 24 Suppl 2 66 70 11758681 (Pubitemid 33061634)
18. Renal disease caused by familial metabolic and hematologic diseases. Finn L, Heptinstall's pathology of the kidney Philadelphia, PA: Lippincott Williams & Wilkins, Jennette JC, Olsen JL, Schwartz MM, Silva FG, 6 2007 1199 1256
19. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J, Ortiz A, Nephrol Dial Transplant 2011 26 1797 1802 10.1093/ndt/gfq306 20504837
20. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy. Valbuena C, Carvalho E, Bustorff M, Ganhao M, Relvas S, Nogueira R, Carneiro F, Oliveira JP, Virchows Arch 2008 453 329 338 10.1007/s00428-008- 0653-2 18769939
21. An association study of inflammatory cytokine gene polymorphisms in Fabry disease. Safyan R, Whybra C, Beck M, Elstein D, Altarescu G, Eur Cytokine Netw 2006 17 271 275 17353161
22. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, Kaneski CR, Mol Genet Metab 2008 95 163 168 10.1016/j.ymgme.2008.06.016 18707907
23. Vasculopathy in patients with Fabry disease: current controversies and research directions. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE, Mol Genet Metab 2010 99 99 108 10.1016/j.ymgme.2009.10.004 19900828
24. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, Noel LH, Grunfeld JP, Valbuena C, Oliveira JP, Muller J, Breunig F, Zhang X, Warnock DG, Nephrol Dial Transplant 2010 25 2168 2177 10.1093/ndt/gfp528 19833663
25. Dysregulated autophagy contributes to podocyte damage in Fabry's disease. Liebau MC, Braun F, Hopker K, Weitbrecht C, Bartels V, Muller RU, Brodesser S, Saleem MA, Benzing T, Schermer B, Cybulla M, Kurschat CE, PLoS One 2013 8 63506 10.1371/journal.pone.0063506 23691056
26. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin Iii HA, Kopp JB, Medicine (Baltimore) 2002 81 122 138 10.1097/00005792-200203000-00003 11889412 (Pubitemid 34218568)
27. Excellent outcome of renal transplantation in patients with Fabry's disease. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B, Transplantation 2000 69 2337 2339 10.1097/00007890-200006150-00020 10868636 (Pubitemid 30408999)
28. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P, Genet Med 2009 11 790 796 10.1097/GIM.0b013e3181bb05bb 19745746
29. Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors. Laney DA, Bennett RL, Clarke V, Fox A, Hopkin RJ, Johnson J, O'Rourke E, Sims K, Walter G, J Genet Couns 2013 22 555 564 10.1007/s10897-013-9613-3 23860966
30. Fabry disease: enzymatic screening using dried blood spots on filter paper. Caudron E, Dermain DP, Prognon P, Rev Med Interne 2010 31 263 S269 21211677
31. Targeted urine microscopy in Anderson-Fabry disease: a cheap, sensitive and specific diagnostic technique. Selvarajah M, Nicholls K, Hewitson TD, Becker GJ, Nephrol Dial Transplant 2011 26 3195 3202 10.1093/ndt/gfr084 21382994
32. Agalsidase benefits renal histology in young patients with Fabry disease. Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E, J Am Soc Nephrol 2013 24 137 148 10.1681/ASN.2012030316 23274955
33. Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine. Maruyama H, Takata T, Tsubata Y, Tazawa R, Goto K, Tohyama J, Narita I, Yoshioka H, Ishii S, Clin J Am Soc Nephrol 2013 8 629 636 10.2215/CJN.08780812 23307880
34. Enzyme replacement therapy and Fabry nephropathy. Warnock DG, Daina E, Remuzzi G, West M, Clin J Am Soc Nephrol 2010 5 371 378 10.2215/CJN.06900909 20007680
35. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classification system in fabry disease. Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, Rolfs A, PLoS Genet 2013 9 1003632 10.1371/journal.pgen.1003632 23935525
36. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ, Nephrol Dial Transplant 2009 24 2102 2111 10.1093/ndt/gfp031 19218538
37. Proteinuria and its consequences in renal disease. Schieppati A, Remuzzi G, Acta Paediatr Suppl 2003 92 9 13 14989459 (Pubitemid 38134742)
38. SOP for Anderson-Fabry disease. National Health Services, http://www.webarchive.org.uk/wayback/archive/20130325153347/http://www. specialisedservices.nhs.uk/library/23/SOP-for-Anderson-Fabry-disease.pdf
39. The value of estimated GFR in comparison to measured GFR for the assessment of renal function in adult patients with Fabry disease. Rombach SM, Baas MC, ten Berge IJM, Krediet RT, Bemelman FJ, Hollak CEM, Nephrol Dial Transplant 2010 25 2549 2556 10.1093/ndt/gfq108 20215390
40. New equations to estimate GFR in children with CKD. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL, J Am Soc Nephrol 2009 20 629 637 10.1681/ASN.2008030287 19158356
41. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N, J Am Soc Nephrol 2007 18 1547 1557 10.1681/ASN.2006080816 17409312 (Pubitemid 46717522)
42. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO, Nephrol Dial Transplant 2006 21 345 354 10.1093/ndt/gfi152 16204287 (Pubitemid 43159987)
43. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Wanner C, Oliveira JP, Ortiz A, Mauer M, Germain DP, Linthorst GE, Serra AL, Marodi L, Mignani R, Cianciaruso B, Vujkovac B, Lemay R, Beitner-Johnson D, Waldek S, Warnock DG, Clin J Am Soc Nephrol 2010 5 2220 2228 10.2215/CJN.04340510 20813854
44. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ, Ann Intern Med 2007 146 77 86 10.7326/0003-4819-146-2-200701160-00148 17179052 (Pubitemid 351640010)
45. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C, Linhart A, Sunder-Plassmann G, Ries M, Beck M, Eur J Clin Invest 2004 34 236 242 10.1111/j.1365-2362.2004.01309.x 15025684 (Pubitemid 38406640)
46. Renal changes in heterozygous Fabry's disease-a family study. Chen HC, Tsai JH, Lai YH, Guh JY, Am J Kidney Dis 1990 15 180 183 2105640
47. Fabry's disease: clinical, pathologic and biochemical manifestations in two Chinese males. Sheu SS, Chan LP, Liao SC, Hsiao KJ, Shu KH, Lu YS, Cheng CH, Lian JD, Zhonghua Yi Xue Za Zhi (Taipei) 1994 54 368 372 7834562
48. Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Ries M, Bettis KEB, Choyke P, Kopp JB, Austin HA, Brady RO, Schiffmann R, Kidney Int 2004 66 978 982 10.1111/j.1523-1755.2004.00846.x 15327390 (Pubitemid 39121001)
49. Prevalence of uncontrolled hypertension in patients with Fabry disease. Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswami U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-Plassmann G, Am J Hypertens 2006 19 782 787 10.1016/j.amjhyper.2006.01.011 16876675 (Pubitemid 44107697)
50. Blood pressure, proteinuria and nephropathy in Fabry disease. Jain G, Warnock DG, Nephron Clin Pract 2011 118 43 48 10.1159/000320903
51. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, Marodi L, Mignani R, Vujkovac B, Beitner-Johnson D, Lemay R, Cole JA, Svarstad E, Waldek S, Germain DP, Wanner C, Nephrol Dial Transplant 2012 27 1042 1049 10.1093/ndt/gfr420 21804088
52. Fabry disease: an underrecognized cause of proteinuria. Fervenza FC, Torra R, Lager DJ, Kidney Int 2008 73 1193 1199 10.1038/sj.ki.5002677 18033242 (Pubitemid 351620425)
53. Treatment of Fabry disease: current and emerging strategies. Rozenfeld P, Neumann PM, Curr Pharm Biotechnol 2011 12 916 922 10.2174/138920111795542705 21235448
54. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V, Jaussaud R, Papo T, Int J Clin Pract 2007 61 293 302 10.1111/j.1742-1241.2006.01237.x 17263716
55. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO, JAMA 2001 285 2743 2749 10.1001/jama.285.21.2743 11386930 (Pubitemid 32525371)
56. Agalsidase alfa and kidney dysfunction in Fabry disease. West M, Nicholls K, Mehta A, Clarke JTR, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R, J Am Soc Nephrol 2009 20 1132 1139 10.1681/ASN.2008080870 19357250
57. Natural course of Fabry disease: changing pattern of causes of death in FOS-Fabry Outcome Survey. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, J Med Genet 2009 46 548 552 10.1136/jmg.2008.065904 19473999
58. Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. Hughes DA, Malmenas M, Deegan PB, Elliott PM, Ginsberg L, Hajioff D, Ioannidis AS, Orteu CH, Ramaswami U, West M, Pastores GM, Jenkinson C, J Med Genet 2012 49 212 220 10.1136/jmedgenet-2011-100407 22315436
59. Age adjusting severity scores for Anderson-Fabry disease. Hughes DA, Ramaswami U, Barba Romero MÃ Deegan P, Mol Genet Metab 2010 101 219 227 10.1016/j.ymgme.2010.06.002 20691627
60. A validated disease severity scoring system for Fabry disease. Giannini EH, Mehta AB, Hilz MJ, Beck M, Bichet DG, Brady RO, West M, Germain DP, Wanner C, Waldek S, Clarke JT, Mengel E, Strotmann JM, Warnock DG, Linhart A, Mol Genet Metab 2010 99 283 290 10.1016/j.ymgme.2009.10.178 19951842
61. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, N Engl J Med 2001 345 9 16 10.1056/NEJM200107053450102 11439963 (Pubitemid 32634266)
62. The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M, Clin J Am Soc Nephrol 2012 7 60 69 10.2215/CJN.03130411 22246281
63. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G, Clin Nephrol 2006 66 77 84 16939062 (Pubitemid 44219432)
64. Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. Pisani A, Visciano B, Roux GD, Sabbatini M, Porto C, Parenti G, Imbriaco M, Mol Genet Metab 2012 107 267 275 10.1016/j.ymgme.2012.08.003 22963910
65. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE, Orphanet J Rare Dis 2013 8 47 10.1186/1750-1172-8-47 23531228
66. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C, J Intern Med 2013 274 331 341 10.1111/joim.12077 23586858
67. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE, J Inherit Metab Dis 2014 [Epub ahead of print]
68. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JTR, Lancet 2009 374 1986 1996 10.1016/S0140-6736(09)61493-8 19959221
69. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M, J Am Soc Nephrol 2007 18 1576 1583 10.1681/ASN.2006111263 17409308 (Pubitemid 46717525)
70. Longitudinal studies on the rate of decline in renal function with age. Lindeman RD, Tobin J, Shock NW, J Am Geriatr Soc 1985 33 278 285 3989190 (Pubitemid 15087125)
71. Receptor-mediated endocytosis of alpha-galactosidase A in human podocytes in Fabry disease. Prabakaran T, Nielsen R, Larsen JV, Sorensen SS, Feldt-Rasmussen U, Saleem MA, Petersen CM, Verroust PJ, Christensen EI, PLoS One 2011 6 25065 10.1371/journal.pone.0025065 21949853
72. Clinical benefit of enzyme replacement therapy in Fabry disease. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C, Kidney Int 2006 69 1216 1221 10.1038/sj.ki.5000208 16609685
73. Fabry disease, enzyme replacement therapy and the significance of antibody responses. Deegan PB, J Inherit Metab Dis 2012 35 227 243 10.1007/s10545-011-9400-y 22037707
74. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, Am J Hum Genet 2004 75 65 74 10.1086/422366 15154115
75. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE, PLoS One 2012 7 47805 10.1371/journal.pone.0047805 23094092
76. A randomised, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of three dosing schedules of agalsidase alfa enzyme replacement therapy for Fabry disease. Hughes DA, Deegan PB, Milligan A, Wright N, Butler LH, Jacobs A, Mehta AB, Mol Genet Metab 2013 109 269 275 10.1016/j.ymgme.2013.04.015 23702393
77. Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A, Genet Med 2009 11 256 264 10.1097/GIM.0b013e3181981d82 19265719
78. Assessment report on the shortage of Fabrazyme. Overview of shortage period: spontaneous reports from June 2009 through 15 September 2010 and registry data from June 2009 through 05 August 2010. European Medicines Agency, http://www.ema.europa.eu/docs/en-GB/document-library/Other/2010/11/WC500099241. pdf Accessed 16-9-2013
79. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Smid BE, Rombach SM, Aerts JM, Kuiper S, Mirzaian M, Overkleeft HS, Poorthuis BJ, Hollak CE, Groener JE, Linthorst GE, Orphanet J Rare Dis 2011 6 69 10.1186/1750-1172-6-69 22041095
80. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. Weidemann F, Kramer J, Duning T, Lenders M, Canaan-Kuhl S, Krebs A, Gonzalez HG, Sommer C, Uceyler N, Niemann M, Stork S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E, J Am Soc Nephrol 2014 25 837 849 10.1681/ASN.2013060585 24556354
81. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Tsuboi K, Yamamoto H, Genet Med 2012 14 779 786 10.1038/gim.2012.39
82. Effects of switching from agalsidase beta to agalsidase alfa in 10 patients with anderson-fabry disease. Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M, JIMD Rep 2013 9 41 48 23430546
83. Effect of reduced agalsidase beta dosage in fabry patients: the Australian experience. Ghali J, Nicholls K, Denaro C, Sillence D, Chapman I, Goldblatt J, Thomas M, Fletcher J, JIMD Rep 2012 3 33 43 23430871
84. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. Tahir H, Jackson LL, Warnock DG, J Am Soc Nephrol 2007 18 2609 2617 10.1681/ASN.2006121400 17656478 (Pubitemid 47378878)
85. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F, JACC Cardiovasc Imaging 2011 4 592 601 10.1016/j.jcmg.2011.01.020 21679893
86. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Valderrabano F, Nephrol Dial Transplant 1996 11 Suppl 7 4 20 9067983 (Pubitemid 27056387)
87. Patients with Fabry disease on dialysis in the United States. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT, Kidney Int 2002 61 249 255 10.1046/j.1523-1755.2002.00097.x 11786107 (Pubitemid 34075152)
88. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy. Mignani R, Feriozzi S, Schaefer RM, Breunig F, Oliveira JP, Ruggenenti P, Sunder-Plassmann G, Clin J Am Soc Nephrol 2010 5 379 385 10.2215/CJN.05570809 20056752
89. Therapeutic implications of renal transplantation in a patient with Fabry's disease. Van den Bergh FA, Rietra PJ, Kolk-Vegter AJ, Bosch E, Tager JM, Acta Med Scand 1976 200 249 256 824932
90. Kidney transplant outcomes in patients with Fabry disease. Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S, Transplantation 2009 87 280 285 10.1097/TP.0b013e318191a842 19155985
91. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease. Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S, J Nephrol 2013 26 645 651 10.5301/jn.5000214 23023720
92. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Pastores GM, Boyd E, Crandall K, Whelan A, Piersall L, Barnett N, Nephrol Dial Transplant 2007 22 1920 1925 10.1093/ndt/gfm096 17395657 (Pubitemid 47244761)
93. Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. Kosch M, Koch HG, Oliveira JP, Soares C, Bianco F, Breuning F, Rasmussen AK, Schaefer RM, Kidney Int 2004 66 1279 1282 10.1111/j.1523-1755. 2004.00883.x 15327428 (Pubitemid 39121039)
94. Females and children with Anderson-Fabry disease: diagnosis, monitoring, benefits of enzyme replacement therapy (ERT) and considerations on timing of starting ERT. Parini R, Feriozzi S, Expert Opin Orphan Drugs 2013 1 315 330 10.1517/21678707.2013.776957
95. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M, Kampmann C, Genet Med 2009 11 441 449 10.1097/GIM.0b013e3181a23bec 19346951
96. Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease. Ishii S, Chang HH, Yoshioka H, Shimada T, Mannen K, Higuchi Y, Taguchi A, Fan JQ, J Pharmacol Exp Ther 2009 328 723 731 10.1124/jpet.108.149054 19106170
97. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. Porto C, Pisani A, Rosa M, Acampora E, Avolio V, Tuzzi MR, Visciano B, Gagliardo C, Materazzi S, la Marca G, Andria G, Parenti G, J Inherit Metab Dis 2012 35 513 520 10.1007/s10545-011-9424-3 22187137
98. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF, Mol Genet Metab 2013 109 86 92 10.1016/j.ymgme.2013. 01.009 23474038
99. Anderson-Fabry disease: developments in diagnosis and treatment. Mehta AB, Int J Clin Pharmacol Ther 2009 47 Suppl 1 66 74
100. Therapeutic goals in the treatment of Fabry disease. Mehta A, West ML, Pintos-Morell G, Reisin R, Nicholls K, Figuera LE, Parini R, Carvalho LR, Kampmann C, Pastores GM, Lidove O, Genet Med 2010 12 713 720 10.1097/GIM.0b013e3181f6e676 20975569
101. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, Ishige N, Suzuki K, Kitagawa T, Sakuraba H, Mol Genet Metab 2010 100 257 261 10.1016/j.ymgme.2010. 03.020 20409739
102. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. Auray-Blais C, Boutin M, Gagnon R, Dupont FO, Lavoie P, Clarke JTR, Anal Chem 2012 84 2745 2753 10.1021/ac203433e 22309310
103. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients. Manwaring V, Boutin M, Auray-Blais C, Anal Chem 2013 85 9039 9048 10.1021/ac401542k 23968398
104. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease. Torralba-Cabeza MÃ Olivera S, Hughes DA, Pastores GM, Mateo RN, Perez-Calvo JI, Mol Genet Metab 2011 104 301 307 10.1016/j.ymgme.2011.06.021 21795086
105. Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. Vylet'al P, Hulkova H, Zivna M, Berna L, Novak P, Elleder M, Kmoch S, J Inherit Metab Dis 2008 31 508 517 10.1007/s10545-008-0900-3 18651238
106. A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wuthrich RP, Serra AL, PLoS One 2011 6 20534 10.1371/journal. pone.0020534 21698285
107. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. Manwaring V, Heywood WE, Clayton R, Lachmann RH, Keutzer J, Hindmarsh P, Winchester B, Heales S, Mills K, J Proteome Res 2013 12 2013 2021 10.1021/pr301200e 23464927